COMMITMENTS AND CONTINGENCIES - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) liability	Dec. 31, 2021 USD ($)	Jul. 29, 2019 USD ($)
Derma Sciences
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Number of liabilities | liability	1
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)	$ 3,000,000
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Payment for contingent consideration	33,300,000
Derma Sciences | Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, liability	200,000	$ 200,000
Arkis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, liability	12,900,000		$ 25,500,000
Business combination, contingent consideration, liability, current	2,800,000
Business combination, contingent consideration, liability, noncurrent	$ 10,100,000
Contingent consideration			13,100,000
Arkis | Milestone Payment One
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, liability			10,000,000
Arkis | Milestone Payment Two
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, liability			$ 15,500,000